Hansoh Pharmaceutical (03692.HK) Reports Annual Results with Shareholders' Profit of RMB 5.555 Billion, Up 27.07% Year-on-Year

Hansoh Pharma(03692) Announcement of Annual Results for the Year Ended December 31, 2025: The Group achieved revenue of RMB 15.028 billion, representing a year-on-year increase of 22.57%; profit attributable to owners of the parent company amounted to RMB 5.555 billion, reflecting a year-on-year growth of 27.07%; basic earnings per share were RMB 0.93. A final dividend of HKD 0.20 per share is proposed.

The announcement stated that the company is a leading innovation-driven pharmaceutical enterprise in China, with the mission of "continuous innovation to improve the quality of human life," focusing on major disease treatment areas such as anti-tumor, anti-infection, central nervous system (CNS), metabolism, and autoimmune diseases. The company has seven innovative drugs produced in China that generate sales revenue, forming a rich product pipeline. For the year ended December 31, 2025, the sales revenue of innovative drugs and cooperative products was approximately RMB 12.354 billion, accounting for about 82.2% of the total income, becoming the core driving force for the sustainable growth of the group's performance.

The company's revenue mainly comes from the sales of pharmaceuticals. The company’s key products are concentrated in the major therapeutic areas that the group strategically focuses on, including anti-tumor, anti-infection, central nervous system, metabolism, and other diseases. The increase in revenue, annual profit, and basic earnings per share during the reporting period was primarily due to the rise in sales revenue from innovative drugs and collaborative products.